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Progranulin (GRN) gene mutations have been genetically associated with frontotemporal dementia (FTD)
and are present in about 23% of patients with familial FTD. However, the neurobiology of this secreted
glycoprotein remains unclear. Here, we report the identiﬁcation of 3 pedigrees of Southern Italian
extraction in whom FTD segregates with autosomal dominant inheritance patterns. We present evidence
that all the available patients in these 3 familial cases are carrying the rare GRN gene exon 6 deletion
g10325_10331delCTGCTGT (relative to nt 1 in NG_007886.1), alias Cys157LysfsX97. This mutation was
previously described in 2 sporadic cases but was never associated with familial cases. Our patients
demonstrate heterogeneous clinical phenotypes, such as the behavioral variant (bv-FTD) in the affected
men and the nonﬂuent/agrammatic variant of primary progressive aphasia (nfvPPA) in the affected
woman. Haploinsufﬁciency was revealed by both quantitative real-time PCR of the gene and protein
analyses. These ﬁndings provide further support for a previously proposed role for the GRN gene in the
genetic etiology of FTD and its phenotypic variability.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Frontotemporal dementia (FTD) represents a heterogeneous
group of progressive neurodegenerative dementias with promi-
nent behavioral alterations and distinct temporal syndromes
associated with sporadic nonﬂuent/agrammatic variant of pri-
mary progressive aphasia (nfvPPA) and semantic disorders
(Cairns et al., 2007; Warren et al., 2013). Early onset dementia
develops in most patients between 45 and 65 years, mostly
exhibiting the presence of local atrophy of frontal and/orhemistry (IBP), CNR, Naples,
ll rights reserved.temporal lobes (Rabinovici and Miller, 2010). About 30%e50% of
cases are familial, with men and women equally affected. The
main subtypes of FTD are the bvFTD, nonﬂuent/agrammatic
variant of primary progressive aphasia (nfvPPA) and corticobasal
degeneration (Gorno-Tempini et al., 2011; Mackenzie et al.,
2009).
GRNmutations were recently reported to be associated with 10%
of total FTD cases and with 23% of patients with a familial FTD
history (Baker et al., 2006; Cruts et al., 2006). To date, the rela-
tionship between GRN mutations and its disease mechanism has
not yet been described, but haploinsufﬁciency has been suggested
to lead to neurodegeneration (Gass et al., 2006; Snowden et al.,
2006; Ward and Miller, 2011).
The g10325_10331delCTGCTGT (relative to nt 1 in NG_007886.1);
alias Cys157LysfsX97mutation, has only been reported in 2 sporadic
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the g10325_10331delCTGCTGT deletion in 3 familial cases that
segregate with FTD and describe the clinical and the molecular
characterization of the patients.
2. Methods
2.1. Participants and study design
The study was approved by the ethics committee of our
institution and all participants signed informed consent. We
enrolled 256 patients and 300 healthy, age-, sex- and geographic
regionematched controls in the study. Patient inclusion criteria
required a diagnosis of frontotemporal dementia (FTD), as
deﬁned by Rascovsky criteria (Rascovsky et al., 2011). Of the
study cohort, 252 individuals had a diagnosis of bvFTD and 4 had
nfvPPA. Among this cohort, we identiﬁed 20 familial cases with
at least 2 individuals affected by dementia; only 1 patient from
each family, who was affected by dementia, was selected for
screening.
2.2. Patients analysis
Blood was collected, and genomic DNA was extracted from
whole blood from the 256 enrolled patients by QIAamp DNA Blood
Mini Kit (QIAGEN). Candidate genes granulin, GRN (NG_007886.1),
andMicrotubule-Associated Protein Tau,MAPT gene (NG_007398.1)
were analyzed by sequencing DNA of one patient in each of the 20
families identiﬁed as described in the previous section. We
sequenced all the coding exons of the GRN gene in these twenty
patients. For the MAPT gene, we opted to start the analysis by
sequencing the exons that were reported to carry the most frequent
mutations, 1, 9e13. No mutations were found in these exons. Sub-
sequently, in the absence of mutations in these exons, we analyzed
the entire gene in the same 20 patients (primers used are detailed
in Table 2A and B in SM). We identiﬁed the mutation in H72 A-FTD2
ﬁrst, then we sequenced the DNA of the second patient H73 from
the same family.
The remaining patients (256 minus 20) and the 300
controls were then all analyzed by PCR-ampliﬁcation-refractory
mutation system (ARMS) only to reveal the identiﬁed mutation
g10325_10331delCTGCTG. PCR ampliﬁcation was performed
with SureCycler 8800 Thermal Cycler (Agilent). Primer se-
quences are reported in Supplementary Materials, Table 2A
and B.
2.3. DNA PCR-ARMS
Exon 6 mutation g10325_10331delCTGCTGT once identiﬁed,
was ampliﬁed by PCR-ARMS technique using normal and
mutated oligonucleotides (Little, 2001; Newton et al., 1989).
Ampliﬁcations were performed with the following primers: 50-
CAT TTT TTC TCA GGC TTC CTG CTG TG-30 (forward Wild Type),
50- GGA CCA TTT TTT CTC AGG CTT CAA G-30 (forward Mut), and
50- GCA GCC AGG ATG GAG GAA ACT-30 (reverse). In each ARMS
reaction, 30 ng of DNA was ampliﬁed in a ﬁnal volume of 20 mL
containing a mixture of 1X Buffer Taq Pol, 0.2-mM dNTPs, 2.5-
mM MgCl2, 0.5 mM of each primer, 0.05 U/mL of Ampli Taq
Gold (Applied Biosystem). Ampliﬁcation conditions were 95 C
for 100, 35 cycles at 95 C for 3000, 62 C for 4000, 72 C for 10, and
an elongation step of 100 at 72 C. PCR-ARMS was analyzed on
1.5% agarose gel electrophoresis, with ethidium bromide 0.5 mg/
mL and visualized with UV light (UVITEC-Cambridge). We per-
formed this test on the 256 patients and 300 controls matched
by age, sex, and geographic region.2.4. Brain imaging
Functional neuroimaging studies were performed in the pa-
tients from the A-FTD2 family. When we started the study, the
affected sister was alive but has since died.
18F-ﬂuorodeoxyglucose Positron Emission Tomography
(18FDG-PET) studies were performed in male patient H72. Brain
images were acquired for 15 minutes in 3-dimensional mode be-
tween 45 and 60 minutes after intravenous injection of 213e250
MBq of 18FDG in a resting state with the eyes closed. The outcome
measure was relative glucose metabolism. To highlight the patterns
of relative metabolic reduction, we used voxel-based Statistical
Parametric Mapping (SPM) analysis of FDG images. Images were
normalized in theMontreal Neurological Institute space using SPM2
(Wellcome Department of Imaging Neuroscience, London, UK). The
patient 18FGD uptake was compared to that of 16 healthy subjects
(mean age 56  12 years, 6 males and 10 females) using the single
subject condition covariate model inwhich age was considered as a
nuisance covariate. SPECT study was performed in female patient
H73 A-FTD2 40 minutes after the intravenous injection of [99mTc]
ethyl cysteinate dimer. Brain images were acquired for 30 minutes.
3. Results
3.1. Genetic analysis by sequencing candidate genes
We sequenced GRN (NG_007886.1) and MAPT (NG_007398.1)
and identiﬁed the g10325_10331delCTGCTGT mutation in GRN exon
6 in patient H72, from family A-FTD2. Then, we extended the
analysis to H73, the female sibling in the same family. We screened
the promoter, the coding regions, and the associated intronic splice
junction. Although a number of polymorphic variants were found in
both the GRN and MAPT genes, we did not identify other functional
polymorphisms andmutations that could have been responsible for
the association. Only g10325_10331delCTGCTGT clearly proved to
segregate with the affected individuals in this family. This deletion
was previously reported in 2 sporadic cases, a female that exhibited
nfvPPA and a male that exhibited bvFTD (Caso et al., 2012; Le Ber
et al., 2008).
We ampliﬁed the exon 6 mutation g10325_10331delCTGCTGT by
the PCR-ARMS test in all of the remaining analyzed recruited pa-
tients and identiﬁed 2 additional mutation carriers: H225 and H153
(Fig. 1A lanes 6e7 and C and lanes 4 and 5). These 2 mutation
carriers were later conﬁrmed to carry the deletion by sequencing
GRN exon 6 (Fig. 2). To exclude the possibility that this was a
common variant, we screened for its presence by PCR-ARMS in the
300 healthy controls matched by age, sex, and geographic origin.
We found no deletions carried by any of these individuals. These
data strongly support the argument for pathogenicity and provide
support for its exclusive association with the disease phenotype
already published as a case report (Caso et al., 2012). However, we
now describe it in 3 familial cases and focus on the exon 6 mutation
g10325_10331delCTGCTGT.
The proband, a male patient, H72 in family A-FTD2 remains the
only patient still alive in the family (Fig. 3, A-FTD2: H72-III2). The
affected sister, H-73, died in 2015 but was alive whenwe started the
study. One male cousin (III-4) was reported to have dementia
characterized by cognitive or behavioral disorders, as did his
mother, the aunt of the proband (II-2) and his uncle (II-1), and the
father of H72-III-2 and H73-III-3 (Fig. 3, A-FTD2).
H72 is a 65-year-old right-handed man who developed prob-
lems with memory as the initial symptom of disease onset and later
followed a course resembling FTD with frontal behavior distur-
bances. Neuropsychological assessment conﬁrmed the presence of
both short-term and long-term auditory verbal memory deﬁcits in
Fig. 1. ARMS-PCR ampliﬁcations. (A) Lanes 2, 4, 6, and 8: ampliﬁcation with Wild type
(Wt) forward primer and Wt reverse primers; lanes 3, 5, 7, and 9: ampliﬁcation with M
forward primer and Wt reverse primer. (B) In the absence of the mutation, only the Wt
primer set is amplifying, as seen in lanes 2 Ctrl2 Wt, 4 Ctrl3 Wt, 6 Ctrl4 Wt, and 8 Ctrl5
Wt, whereas ampliﬁcation with the forward M and Wt reverse primer sets fail in lanes
3, Ctrl2 M; 5, Ctrl3 M; 7, Ctrl4 M; and 9, Ctrl5 M. (C) Lanes 2 and 4: ampliﬁcation with
Wt forward and Wt reverse primers; lanes 3 and 5: ampliﬁcation with M forward and
Wt reverse primer. H72 mutant was used as a positive mutant control.
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daily living functioning capacity.
The ﬁrst PET study, performed at the age of 60, revealed a mild
decrease in cerebral FDGuptake in the leftmedial frontal andmedial
temporal cortices as well as in the left posterior cingulate (Fig. 4A).
The second PET study, performed 1 year later at the age of 61,
demonstrated that the 18FDG uptake was further reduced in the
posterior cingulate and in the frontal cortex, and that at this point,
the hypometabolism also involved the right hemisphere. Moreover,
reduced 18FDG uptake was also observed in the superior parietal
cortex/precuneus bilaterally (Fig. 4C). These changes are clearly
highlighted by the SPM statistical analysis as shown in Fig. 4B and D.The female patient, H73 Family A-FTD2 died in 2015 at the age of
61. She started to have a severe and rapidly progressive language
deﬁcit at age 58 years. She became less expressive in speech and
began having difﬁculty in ﬁnding appropriate words to context.
These impediments were associated with impaired ability to repeat
sentences and phrases. Later, she exhibited apraxia and agramma-
tism and progressive nonﬂuent aphasia with word-ﬁnding difﬁ-
culty. At the age of 58, the mini-mental state examination score was
very low, mostly due to the patient being totally aphasic, with a
Progressive Aphasia Severity Scale (PASS ¼ 3) score of only 5/30
(Sapolsky et al., 2014). The diagnosis was logopenic/phonological
aphasia according to the Gorno-Tempini classiﬁcation, presenting a
nfvPPA (Gorno-Tempini et al., 2011). SPECT images showed hypo-
perfusion in the left frontotemporal and parietal cortices
(Supplementary Fig. 1).
Male Patient H225, family B-FTD7 (Fig. 3, B-FTD7: H225-II7) was
a 59-year-old right-handed man, who was referred at age of
57 years to the Memory Clinic with memory and behavioral dis-
turbances. At 56-year old, he started to suffer behavioral changes
with a spectrum that spanned from agitation/wondering to lack of
motivation/loss of interest, apathy with language disturbances, and
abnormal appetite/eating. Neurologic examination revealed
postural instability, loss of reﬂex, decreased grasping ability of the
right hand, and a positive Epstein sign. He had echolalia and a high
latency in verbal responses. A family history of dementia was re-
ported. His mother was reported to have behavioral disturbances,
affected primarily in speech production.
Male Patient H153, family C-FTD10 was an 81-year-old right-
handed man, referred at age 78 years with attention and behav-
ioral disturbances. During young adult life, he suffered depressive
moods that were successfully treated with antidepressants. At the
age of 73, he had a myocardial infarction. At age 78 years, after his
brother’s death, he regressed into depressive moods and exhibited
FTD symptoms, including loss of initiative, unstable equilibrium,
dizziness and confusion. Drug therapy was ineffective and he
became passive and purposeless. Neurologic examination exhibited
postural instability and loss of reﬂexes. Two sisters were reported
by relatives to be affected by dementia, but we do not have further
clinical records in regard.
4. Mutation functional analyses
To understand how the mutation was affecting the protein
expression of the patients, we analyzed plasma proteins byWestern
blot (Fig. 5CeE). Our data demonstrate a decreased protein
expression in the plasma of patients H72, H73, and H225 (Fig. 5C,
and lanes 1, 2, and 3) when compared to controls (Fig. 5C, and lanes
4e5), corresponding to the described protein haploinsufﬁciency
phenotype in these individuals.
GRN gene expression was later analyzed by quantitative real-
time PCR of total RNA extracted from white blood cells (WBC)
with a primer set corresponding to a site downstream of the mu-
tation. Speciﬁcally, our primers were designed to correspond to
sequences within ex7 and ex8 downstream of the mutation
(Fig. 5A). Our results demonstrate that the quantity of messenger
RNA (mRNA) molecules containing ex7 and ex8 is increased inWBC
from patients carrying the g10325_10331delCTGCTGT mutation as
compared to controls (Fig. 5A and Supplementary Fig. 2). We
further analyzed mRNA expression using a primer set corre-
sponding to sequences within the ex6 g10325_10331delCTGCTGT
mutation. The data, in Fig. 5B, show that the quantity of mRNA
molecules containing wild type ex6 decreased and strongly corre-
lated with the decreased protein levels observed in the Western
blot analysis (Fig. 5CeE). This is also consistent with heterozygosity
for the mutation in patient H72.
Fig. 2. Sanger sequencing electropherograms of the exon 6 GRN gene-mutated region in the FTD patients. Analyses were done by Sanger-based method sequencing. All the 13 exons
of the GRN gene were investigated (NG_007886.1). Primers were designed to include exon-intron boundaries and 50 and 30 regulatory regions. PCR ampliﬁcations were performed on
SureCycler 8800 Thermal Cycler (Agilent). (A) and (B) Exon 6 GRN electropherogram of the mutated region corresponding to H72 and H73 in family A-FTD2. (C) Exon 6 GRN
electropherogram of the mutated region of Patient H225, family B-FTD7. (D) Exon 6 GRN electropherogram of the mutated region of Patient H153, family C-FTD10. The arrows show
the position of the mutation. Abbreviations: FTD, frontotemporal dementia; PCR, polymerase chain reaction.
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Fig. 3. Pedigrees A-FTD2, B-FTD7, and C-FTD10. Filled symbols represent affected individuals, empty symbols represent unaffected individuals. Symbols with diagonal lines
represent deceased individuals. Probands are indicated by arrows; (A) FTD2, Proband H72-III2 is a man with a bvFTD phenotype, H73-III3 is his deceased affected sister with nfvPPA;
(B) FTD7, H225-III7 is a man with bvFTD; and (C) FTD10, Proband H153-II2 is a man with bvFTD. Abbreviation: FTD, frontotemporal dementia.
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The controls reported in the Fig. 5A and Bwere prepared froma pool
of 5 controls. The same preparationwas used in these experiments.
5. Discussion
This study identiﬁed a g10325_10331delCTGCTGT deletion in
exon 6 of the GRN gene in 4 patients available for analysis from 3families from Southern Italy who have positive family histories for
FTD. The 2 patients in family A-FTD2 exhibited differing pheno-
types, bvFTD in the male and nfvPPA in the female. Male patients
H225 in B-FTD7 and H153 in C-FTD10 exhibited bvFTD phenotype,
consistent with the clinical heterogeneity associated with the same
mutation.
The results of PET and SPECT studies from patients of family
A-FTD2 disclosed patterns of hypometabolism and hypoperfusion
Fig. 4. Patient H72 18F FDG-PET scans. Axial slices of 18F FDG-PET uptake obtained in patient H72 at different brain levels from the cerebellum to the centrum semiovale at the ﬁrst
(A and B) compared to the second (C and D) study; slight hypometabolism is evident in the left medial temporal cortex, frontal cortex and posterior cingulate at the ﬁrst study,
indicated by the upper and lower arrows. (B) and (D) demonstrate clusters of FDG reduction superimposed on a volume obtained from a normal brain for anatomic reference at the
ﬁrst (B) and the second (D) study. The relative glucose hypometabolism appears more widespread in the second study (C and D) and involves both frontal and parietal cortices. SPM
analysis highlights the location of the hypometabolic deﬁcit in our patient as compared to controls (p < 0.05 uncorrected for voxel height). The FDG images of each PET study were
scaled to the maximum percentage of the global radioactive concentration. The color scale represents the lower (blue) and the higher (red) cerebral radioactive 18FDG concentration
values. Abbreviations: An, anterior; FDG-PET, 18F-ﬂuorodeoxyglucose positron emission tomography; FTD, frontotemporal dementia; L, left; P, posterior; R, right. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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patient. The PET study, initially showed hypometabolism involving
the hippocampus and the posterior cingulate in patient H72, which
may be related to the prevalent amnesic syndrome observed at the
beginning of the symptoms. The subsequent progression of his
behavioral and frontal disturbances corresponded to the further
reduction of frontal hypometabolism found at the second PET study.
This was also observed in prior studies of patients with GRN mu-
tations. These studies reported that the disease progressed toward
Alzheimer’s disease or FTD from an initial amnestic mild cognitive
impairment diagnosis (Kelley et al., 2010; Petersen et al., 1999).
Other studies reported associations of temporoparietal atrophy
with progranulin mutations, demonstrating a pattern analogous to
the one observed in our patient. However, hypometabolism
patterns reported in association with different gene mutations are
quite heterogeneous (Seelaar et al., 2011). Moreover, differentiating
these patterns in patients with advanced disease status will likely to
be much more difﬁcult. Early imaging used for diagnosis could be
much more helpful (Le Ber et al., 2008; Whitwell et al., 2012). It is
possible that the left frontotemporal and parietal hypoperfusion
observed with the SPECT study in patient H73 is related to the
diagnosis of nfvPPA. A similar pattern was observed with the 18F-
ﬂuorodeoxyglucose Positron Emission Tomography study in a pa-
tient presenting sporadic mutation and nfvPPA.
This mutation was already described in 2 apparently sporadic
cases: a female FTD patient presenting nfvPPA phenotype and a
male patient with bvFTD (Caso et al., 2012; Le Ber et al., 2008). A
speculation that mutations of the GRN gene might exert differentphenotypes according to the sex of the mutation carrier is prema-
ture and not supported by the small number of cases but would
certainly merit further study. Functional correlates may be hy-
pothesized from preclinical studies. Progranulin (PGRN) functions
as a neurotrophic factor regulating neurite outgrowth and pro-
moting neuronal survival (Ryan et al., 2009; Van Damme et al.,
2008). It was also reported that PGRN can play a secretion-
independent role because it acts as a promoter-speciﬁc transcrip-
tional repressor (Hoque et al., 2010).
Gene expression analysis using a primer set designed to corre-
spond to sequences within the ex6 g10325_10331delCTGCTGT
mutation conﬁrms that the GRN gene expression corresponded to
the heterozygosity in the mutation in patient H72. In fact, our data
show that the quantity of mRNA molecules containing wild type
ex6 decreased and strongly correlated with the decreased protein
levels observed in theWestern blot analysis (Fig. 5CeE). The results
of the analysis also correlated with the decreased protein quantity
observed in the Western analysis of the plasma in the same
patients. We do not yet have a complete understanding of the na-
ture of the increase in transcripts observed with a different primer
set (ex 7, ex 8 Fig. 5A), and further analyses need to be carried out.
Previous studies aimed at examining the relationship between
protein and transcript levels revealed that transcript levels in
eukaryotic cells provide little predictive value of the extent of
protein expression (Guo et al., 2008; Gygi et al., 1999). The mode of
inheritance is autosomal dominant with a spectrum of clinical
presentations highly heterogeneous (Finch et al., 2009; Sleegers
et al., 2009).
Fig. 5. GRNmRNA levels in WBC samples (A, B) and PGRN protein-expression (C, D, and E) in plasma samples from FTD patients. Diagrams in ﬁgures (A, B) express the relative level
of each mRNA analyzed (A) using primers in ex 7 (forward) and ex 8 (reverse). (A) mRNA analysis in WBC samples from FTD patients H72, H73, and H225 is shown and compared to
healthy controls. (B) mRNA analysis results in WBC samples from FTD patient H72 as compared to healthy control subjects when primers in ex 6 (forward) and ex 8 (reverse) were
used. Both were compared to the internal standard glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from 3 independent assays. Results are represented as means  standard
error of the mean (SEM) of the 3 experiments. Ctrls represent the mean of the same pool of selected control samples. (C), (D), and (E) Western blotting analysis of PGRN protein in
plasma samples from FTD patients H72, H73, and H225 (lanes 1e3) and from healthy controls (lanes 4, 5), with fetal bovine serum (lane 6) as a negative control. Part label C is
representative of 3 Western blots; part label D represents Coomassie blue staining of the gel; and E shows a graph of the densitometric analysis of the signal intensity from all 3
assays normalized against albumin (66.5 KDa), the major component of the total plasma protein signal obtained by Coomassie blue staining of the gels. Results are represented as
means  SEM of the 3 experiments. *p < 0.05 versus healthy patients. Abbreviations: FTD, frontotemporal dementia; mRNA, messenger RNA; PGRN, progranulin. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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determined, our ﬁndings are consistent with a prior hypothesis that
it could be essential for neuronal survival (Ward and Miller, 2011).
GRN is expressed in many tissues and mediates its role in devel-
opment by activating signaling cascades that control cell-cycle
progression and cell motility (Nedachi et al., 2011).
The reported GRN mutation was not found in 300 healthy
controls without any behavioral and cognitive disturbances, as
analyzed by PCR-ARMS, suggesting that this PGRN mutation is
characteristic of patients with FTD. Future investigations will
focus on understanding how GRN is involved in neuro-
degeneration, speciﬁcally on development of different FTD
phenotypes.Disclosure statement
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